Factors Associated with the Effects of Ipragliflozin on the Diurnal Profiles of Plasma Glucose and 3-hydroxybutyrate in Patients with Type 2 Diabetes

被引：0
|
作者：
Nakayama, Hitomi
Yoshinobu, Satoko
Kawano, Seiko
Tsuruta, Munehisa
Nohara, Masayuki
Hasuo, Rika
Akasu, Shoko
Tokubuchi, Ichiro
Wada, Nobuhiko
Hirao, Saori
Iwata, Shinpei
Kaku, Hiroo
Otabe, Shuichi
Tajiri, Yuji
Yamada, Kentaro
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1236-P
引用
收藏
页码：A320 / A320
页数：1
相关论文
共 50 条
  • [1] Effects of a sodium glucose co-transporter2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type2 diabetes: A study using continuous glucose monitoring
    Yamada, Kentaro
    Nakayama, Hitomi
    Yoshinobu, Satoko
    Kawano, Seiko
    Tsuruta, Munehisa
    Nohara, Masayuki
    Hasuo, Rika
    Akasu, Shoko
    Tokubuchi, Ichiro
    Wada, Nobuhiko
    Hirao, Saori
    Iwata, Shinpei
    Kaku, Hiroo
    Tajiri, Yuji
    JOURNAL OF DIABETES INVESTIGATION, 2015, 6 (06) : 699 - 707
  • [2] Effects of β-hydroxybutyrate on cognition in patients with type 2 diabetes
    Jensen, Nicole Jacqueline
    Nilsson, Malin
    Ingerslev, Jonas Schultz
    Olsen, Dorte Aalund
    Fenger, Mogens
    Svart, Mads
    Moller, Niels
    Zander, Mette
    Miskowiak, Kamilla Woznica
    Rungby, Jorgen
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2020, 182 (02) : 233 - 242
  • [3] Factors with remission of fatty liver in patients With type 2 diabetes treated with ipragliflozin
    Yamauchi, Yuki
    Nakamura, Akinobu
    Takahashi, Kiyohiko
    Takase, Takahiro
    Yamamoto, Chiho
    Yokota, Isao
    Atsumi, Tatsuya
    Miyoshi, Hideaki
    ENDOCRINE JOURNAL, 2019, 66 (11) : 995 - 1000
  • [4] Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects
    Takase, Takahiro
    Nakamura, Akinobu
    Miyoshi, Hideaki
    Yamamoto, Chiho
    Atsumi, Tatsuya
    ENDOCRINE JOURNAL, 2017, 64 (03) : 363 - 367
  • [5] The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography
    de Kreutzenberg, S. Vigili
    Avogaro, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2017, 40 (06) : 627 - 634
  • [6] The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography
    S. Vigili de Kreutzenberg
    A. Avogaro
    Journal of Endocrinological Investigation, 2017, 40 : 627 - 634
  • [7] DIURNAL-VARIATIONS IN BLOOD-GLUCOSE, 3-HYDROXYBUTYRATE, ACETOACETATE, PLASMA FREE FATTY-ACIDS AND GLYCEROL IN DIABETICS
    ROOTH, G
    CARLSTROM, S
    ACTA MEDICA SCANDINAVICA, 1972, 191 (06): : 559 - +
  • [8] Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
    Ueno, Hiroaki
    Nakazato, Hiroko
    Ebihara, Emi
    Noma, Kenji
    Kawano, Takahisa
    Nagamine, Kazuhiro
    Sakoda, Hideyuki
    Nakazato, Masamitsu
    DIABETES THERAPY, 2018, 9 (01) : 403 - 411
  • [9] Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study
    Hiroaki Ueno
    Hiroko Nakazato
    Emi Ebihara
    Kenji Noma
    Takahisa Kawano
    Kazuhiro Nagamine
    Hideyuki Sakoda
    Masamitsu Nakazato
    Diabetes Therapy, 2018, 9 : 403 - 411
  • [10] Effects of Nateglinide Versus Acarbose on Postprandial Plasma Glucose Excursion and Postprandial Lipid Profiles in Patients with Type 2 Diabetes
    Lu, Juming
    Lv, Xiaofeng
    Xue, Yaoming
    Guo, Xiaohui
    Li, Yanbing
    Yan, Li
    DIABETES, 2011, 60 : A291 - A292
12345